In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Nuwellis has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.

Earnings and Revenue Growth Forecasts

NasdaqCM:NUWE - Analysts future estimates and past financials data (USD Millions)
Date	Revenue	Earnings	Free Cash Flow	Cash from Op	Avg. No. Analysts
3/31/2026	9	-19	-12	-11	N/A
12/31/2025	8	-18	-11	-11	N/A
9/30/2025	8	-17	-9	-9	N/A
6/30/2025	8	-15	-9	-9	N/A
3/31/2025	9	-10	-9	-9	N/A
12/31/2024	9	-11	-10	-10	N/A
9/30/2024	9	-17	-11	-11	N/A
6/30/2024	9	-23	-12	-12	N/A
3/31/2024	9	-20	-15	-15	N/A
12/31/2023	9	-23	-18	-18	N/A
9/30/2023	9	-17	-19	-18	N/A
6/30/2023	8	-17	-18	-18	N/A
3/31/2023	8	-17	-17	-16	N/A
12/31/2022	9	-15	-15	-15	N/A
9/30/2022	8	-17	-16	-16	N/A
6/30/2022	8	-18	-18	-17	N/A
3/31/2022	8	-19	-18	-17	N/A
12/31/2021	8	-20	-18	-18	N/A
9/30/2021	8	-18	-17	-17	N/A
6/30/2021	8	-17	-17	-17	N/A
3/31/2021	8	-17	-17	-16	N/A
12/31/2020	7	-18	-17	-17	N/A
9/30/2020	7	-19	-17	-17	N/A
6/30/2020	6	-19	-17	-16	N/A
3/31/2020	6	-20	-17	-17	N/A
12/31/2019	6	-23	N/A	-16	N/A
9/30/2019	6	-22	N/A	-15	N/A
6/30/2019	6	-22	N/A	-15	N/A
3/31/2019	5	-22	N/A	-14	N/A
12/31/2018	5	-17	N/A	-15	N/A
9/30/2018	4	-29	N/A	-15	N/A
6/30/2018	4	-27	N/A	-15	N/A
3/31/2018	4	-27	N/A	-15	N/A
12/31/2017	4	-25	N/A	-12	N/A
9/30/2017	3	-14	N/A	-11	N/A
6/30/2017	3	-15	N/A	-13	N/A
3/31/2017	2	-16	N/A	-12	N/A
12/31/2016	1	-18	N/A	-16	N/A
9/30/2016	1	-19	N/A	-18	N/A
6/30/2016	N/A	-22	N/A	-19	N/A
3/31/2016	N/A	-24	N/A	-22	N/A
12/31/2015	0	-27	N/A	-23	N/A
9/30/2015	0	-27	N/A	-24	N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: Insufficient data to determine if NUWE's forecast earnings growth is above the savings rate (3.5%).

Earnings vs Market: Insufficient data to determine if NUWE's earnings are forecast to grow faster than the US market

High Growth Earnings: Insufficient data to determine if NUWE's earnings are expected to grow significantly over the next 3 years.

Revenue vs Market: Insufficient data to determine if NUWE's revenue is forecast to grow faster than the US market.

High Growth Revenue: Insufficient data to determine if NUWE's revenue is forecast to grow faster than 20% per year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: Insufficient data to determine if NUWE's Return on Equity is forecast to be high in 3 years time

Discover growth companies

Company Analysis and Financial Data Status

Data	Last Updated (UTC time)
Company Analysis	2026/07/05 10:14
End of Day Share Price	2026/07/02 00:00
Earnings	2026/03/31
Annual Earnings	2025/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

Package	Data	Timeframe	Example US Source ^*
Company Financials	10 years	Income statement Cash flow statement Balance sheet	SEC Form 10-K SEC Form 10-Q
Analyst Consensus Estimates	+3 years	Forecast financials Analyst price targets	Analyst Research Reports Blue Matrix
Market Prices	30 years	Stock prices Dividends, Splits and Actions	ICE Market Data SEC Form S-1
Ownership	10 years	Top shareholders Insider trading	SEC Form 4 SEC Form 13D
Management	10 years	Leadership team Board of directors	SEC Form 10-K SEC Form DEF 14A
Key Developments	10 years	Company announcements	SEC Form 8-K

^* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Nuwellis, Inc. is covered by 10 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

Analyst	Institution
Jan Wald	Benchmark Company
Sean Lavin	BTIG
Jason Mills	Canaccord Genuity

Nuwellis Future Growth

Future criteria checks 0/6

Key information

Recent future growth updates

Nuwellis Provides Revenue Guidance for Third Quarter Ended September 30, 2024

Consensus EPS estimates upgraded to US$2.69 loss

Price target decreased by 36% to US$6.00

Consensus revenue estimates fall by 19%

Price target decreased by 27% to US$16.00

Consensus EPS estimates upgraded to US$13.08 loss

Recent updates

Nuwellis, Inc. Announces Chief Executive Officer Changes, Effective June 30, 2026

Nuwellis, Inc. Announces Transition of John Erb from the Role as President

Nuwellis, Inc. has completed a Follow-on Equity Offering in the amount of $6 million.

Nuwellis, Inc. has filed a Follow-on Equity Offering.

Nuwellis Inc Announces Successful Completion of Fda Pre-Submission 510(K) Meeting to Expand Aquadex Label

Nuwellis, Inc. to Report Q1, 2026 Results on May 12, 2026

Nuwellis, Inc. Announces Receipt Of Notice Of Allowance For Dual Lumen Midline Catheter Technology

Nuwellis, Inc. Announces Aquadex Software Update

Nuwellis, Inc., Annual General Meeting, Apr 28, 2026

Nuwellis, Inc. Announces Board of Directors Changes, Effective March 26, 2026

Nuwellis, Inc. (NasdaqCM:NUWE) completed the acquisition of Rendiatech Ltd.

Nuwellis, Inc. Appoints Stuart L. Goldstein as Director of Clinical Strategy

Nuwellis Appoints David A. Mcdonald and Martin J. Emerson to Board of Directors, Effective February 24, 2026

Nuwellis, Inc. to Report Q4, 2025 Results on Mar 10, 2026

Nuwellis, Inc. Announces the Appointment of Carisa Schultz as the Principal Financial Officer, and Principal Accounting Officer, Effective from February 2, 2026

Nuwellis, Inc. Appoints Carisa Schultz as Chief Financial Officer, Effective February 2, 2026

Nuwellis, Inc. Announces Changes to Board of Directors, Effective January 21, 2026

Nuwellis, Inc. Announces the Presentation of New Real-World Data from New York City's Lenox Hill Hospital at the 2025 American Society of Nephrology (ASN) Kidney Week

Nuwellis, Inc. Receives Notice of Allowance of A New U.S. Patent Strengthening Vivian™? Pediatric System with Advanced Clamp Safety Technology

Nuwellis, Inc. to Report Q3, 2025 Results on Nov 12, 2025

Nuwellis, Inc. Announces 92% Survival in Children with Acute Kidney Injury, Fluid Overload or Congenital Kidney Failure Following Treatment with Aquadex®

Nuwellis Introduces New 24-Hour Aquadex™? Circuit to Support Hospital-Based Outpatient and Short-Term Fluid Management

Nuwellis, Inc. has filed a Follow-on Equity Offering in the amount of $4.65 million.

Nuwellis, Inc. Receives FDA 510(k) Clearance for New Dual Lumen Extended Length Catheter

Nuwellis, Inc. to Exit International Operations to Accelerate U.S. Revenue Growth and Strategic Focus

Nuwellis, Inc. to Report Q2, 2025 Results on Aug 12, 2025

Nuwellis Announces Termination of REVERSE-HF Clinical Trial to Focus on Strategic Growth in Outpatient Heart Failure Care

Nuwellis, Inc. Appoints John L. Erb as the President

Nuwellis Receives Non-Compliance Letter from Nasdaq Regarding Minimum Bid Price Requirement

Nuwellis, Inc. has completed a Follow-on Equity Offering in the amount of $4.346418 million.

Nuwellis, Inc. has filed a Follow-on Equity Offering in the amount of $9.999461 million.

Nuwellis, Inc. to Report Q1, 2025 Results on May 13, 2025

Nuwellis, Inc., Annual General Meeting, May 20, 2025

Nuwellis, Inc. Announces CEO Changes

Nuwellis, Inc Highlights Promising Findings from Updated Analysis of the AVOID-HF Study

Nuwellis, Inc. to Report Q4, 2024 Results on Mar 11, 2025

Nuwellis Provides Revenue Guidance for Third Quarter Ended September 30, 2024

Nuwellis, Inc. to Report Q3, 2024 Results on Nov 11, 2024

Seastar Medical Holding Corporation Enters into Confidential Settlement Agreement and Release with Nuwellis

Nuwellis, Inc. has completed a Follow-on Equity Offering in the amount of $0.891783 million.

Nuwellis, Inc. has filed a Follow-on Equity Offering in the amount of $0.916782 million.

Nasdaq Panel Grants Nuwellis Continued Listing on the Nasdaq Stock Market, Subject to Conditions

Nuwellis Announces First Pediatric Patient Treated in A Commercial Setting with Seastar Medical's Quelimune Therapy At Cincinnati Children's

Nuwellis, Inc. has filed a Follow-on Equity Offering in the amount of $1.990002 million.

Nuwellis, Inc. to Report Q2, 2024 Results on Aug 13, 2024

Nuwellis Marks First Commercial Sale of Quelimune Therapy to Cincinnati Children's

Nuwellis, Inc. Announces New Clinical Evidence Demonstrating the Efficacy of its Aquadex® System to be Presented at HFSA 2024 Conference

Nuwellis Receives Non-Compliance Letter from Nasdaq Regarding Minimum Stockholders' Equity Requirement

First quarter 2024 earnings: EPS exceeds analyst expectations while revenues lag behind

Nuwellis, Inc. Receives USPTO Notice of Patent Allowance for Innovative Pediatric CRRT Technology

Nuwellis, Inc. to Report Q1, 2024 Results on May 07, 2024

Nuwellis, Inc. Announces Launch of Ultrafiltration Therapy Using Aquadex Smartflow® System at Henry Ford Health

Consensus EPS estimates upgraded to US$2.69 loss

Nuwellis, Inc. Announces Results from Two New Clinical Data Analyses from the AVOID-HF Trial, Which Demonstrate the Benefits of its Aquadex System in Reducing Heart Failure Readmissions at 30 Days

Full year 2023 earnings: EPS exceeds analyst expectations

Nuwellis, Inc. to Report Q4, 2023 Results on Mar 05, 2024

New major risk - Share price stability

Nuwellis, Inc. Receives FDA Clearance for an Additional Dual Lumen Extended Length Peripheral Catheter

Nuwellis Receives Non-Compliance Notice from Nasdaq

Nuwellis, Inc. Announces New Real-World Data Highlight the Clinical Benefits of Ultrafiltration Therapy with Hematocrit Monitoring Foriatric Patients

Price target decreased by 36% to US$6.00

Third quarter 2023 earnings: EPS and revenues exceed analyst expectations

New major risk - Revenue and earnings growth

Less than half of directors are independent

Nuwellis, Inc. Announces Board of Directors Transition

Nuwellis, Inc. to Report Q3, 2023 Results on Nov 07, 2023

Nuwellis, Inc. has completed a Composite Units Offering in the amount of $2.25 million.

Nuwellis Provides Regulatory Update on Seastar Medical's Selective Cytopheretic Device Use in Pediatric Acute Kidney Injury Under A Humanitarian Device Exemption

New major risk - Share price stability